BioPharma
Queen Street Analytics' weekly digest of regulatory developments, legislative discussions, political announcements and other government-related news in biotech, pharmaceutical manufacturing, drug distribution and pricing, the life sciences and medical research.
QSA's Week in BioPharma (#20, 2025)
Major pharma partnership for IND filing; bio innovation grants in Alberta; new domestic vaccine initiative; European patent grant notice; Senators speak on research security, microplastics; MPs address vaccination, fentanyl sentencing.
QSA's Week in BioPharma (#19, 2025)
AI drug discovery platforms launched; expanded R&D in Munich; hemophilia A clinical trial updates; inducement grants disclosed; conference participation announced.
QSA's Week in BioPharma (#18, 2025)
Competition Bureau investigates BWX-Kinectrics deal; Surtax remission order for biopharma imports; Tariff relief for medical goods; MPs discuss pharmacare rollout; Senator comments on research funding.
QSA's Week in BioPharma (#17, 2025)
AstraZeneca expands biopharma research footprint; Northstrive Biosciences files new US patents; Adial Pharmaceuticals secures IP for genetic-based treatments; ABVC BioPharma targets mental health market; PCI Pharma completes major US acquisition.
Lobbying Landscapes in BioPharma (Apr, 2025)
Centre for the Commercialization of Regenerative Medicine; Terry Fox Research Institute; Emergent BioSolutions Canada Inc.; Novo Nordisk Canada Inc.; INTERVAC - INTERNATIONAL VACCINE CENTRE; Janssen Inc.
QSA's Week in BioPharma (#16, 2025)
MPs debate pharmacare; mental health and hospital investment raised; AI research funding cuts discussed; patent and bioscience advances reported; provincial innovation funding expands.